Rare Diseases: Drugs
Commons · Question 94611 · Tabled 25 Nov 2025 · Department of Health and Social Care · Official record
Answered 1 Dec 2025
Question
Asked by Joshua Reynolds
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the suitability of the National Institute for Health and Care Excellence’s approach to evaluating the cost-effectiveness of rare disease medicines.
Answer
Answered by Zubir Ahmed, 1 Dec 2025
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent a clinically and cost-effectiv...